Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for asfotase alfa

  1. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST23)

    Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in babies, children, young people and adults.

    Highly specialised technologies guidance
    Published
    1 March 2023
    View recommendations

    Sections for HST23

  2. Past appeals and decisions

    pemetrexed 6 June 2007 TBC Lysosomal acid lipase deficiency - sebelipase alfa 25 April 2017 TA068 Macular degeneration (age-related) -...

  3. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

    Highly specialised technologies guidance
    Published
    2 August 2017